I’ve spent my career watching health systems grind against human biology, and the way we handle chronic disease has become a kind of institutionalized frustration. It’s not that we lack good therapies. We have them. The issue is the money architecture. American health insurance actively punishes the very behaviors that keep chronically ill people stable. Every formulary restriction, every prior authorization hurdle, every January 1st deductible reset—these are design choices with utterly predictable downstream effects: treatment interruptions, disease progression, avoidable emergency visits. The insurance apparatus doesn’t just fail to support chronic disease management. It builds an obstacle course and asks sick, exhausted people to run it while their own pathophysiology weighs them down.
The Structural Misalignment Between Insurance Cycles and Disease Biology
Chronic diseases don’t care about the calendar year. Type 2 diabetes, hypertension, persistent depressive disorder, rheumatoid arthritis—these are continuous biological processes. They demand steady medication adherence, regular monitoring, and stable relationships with clinicians. Yet the insurance model we’ve normalized runs on a 12-month contract that resets deductibles, shuffles formularies, and rejiggers provider networks every single year. This isn’t a minor inconvenience. It’s a design flaw that manufactures gaps in care.
Take someone with well-controlled hypertension on a fixed-dose ARB and diuretic. By November, they’ve blown through their deductible and out-of-pocket max. Copay is zero. January hits and the deductible resets. That same prescription suddenly demands $147 until the deductible is satisfied again. Faced with competing bills, the patient halves the dose to stretch a 30-day supply into 45. Within weeks, blood pressure starts climbing. The predictable endpoint is a stroke or a cardiac event that costs the system exponentially more than the pills ever did. The insurance design didn’t cause the hypertension, but it manufactured the non-adherence.
And it’s not just meds. Specialist visits, lab monitoring, durable medical equipment—all of it gets hit by the January price shock. A person with type 1 diabetes needs quarterly HbA1c tests and an annual retinal screen. When the lab work alone costs $380 before the deductible is met, that first-quarter visit gets skipped. The insurer hasn’t denied the care. It’s just priced it out of reach exactly when continuity matters most. The actuarial model behind this assumes consumers will make rational trade-offs. It ignores the behavioral economics of being sick, where short-term financial pain steamrolls long-term health logic.
Formulary Churn as a Mechanism of Instability
Pharmacy benefit managers and insurers renegotiate drug formularies every year, usually under the banner of cost control. For an acute problem, swapping one NSAID for another is no big deal. For chronic conditions—especially when psychotropic or immunomodulatory drugs are involved—switching a stable patient from something that works to a supposedly bioequivalent alternative is not bioequivalent. A patient with bipolar disorder who’s finally found euthymia on a specific extended-release lithium brand can relapse if forced onto an immediate-release generic with different pharmacokinetics. The insurer’s formulary committee, staring at population-level spreadsheets, sees only a cost-saving opportunity. The actual human being experiences the unraveling of a hard-won therapeutic equilibrium.
And the appeal burden lands squarely on the prescriber and the patient. A prior authorization request means clinical documentation proving the alternative is medically necessary. This eats 20 to 40 minutes of physician time per request—time that’s unbillable and directly subtracts from face-to-face care. Smaller practices with thin administrative staff get hit hardest. So many clinicians just prescribe whatever is on the formulary, even when they know it’s suboptimal, because the alternative is a paperwork war they can’t win. The insurer has quietly shifted clinical decision-making from the exam room to a corporate pharmacy and therapeutics committee.
Step Therapy and the Forced Failure Protocol
Step therapy—or “fail first”—is a utilization management tool that forces patients to try and fail on one or more cheaper drugs before the insurer will cover the one their doctor actually wants. The clinical logic says older, cheaper drugs often work and should be tried first. That holds for many conditions, sure. It collapses when you’re dealing with diseases that have messy, heterogeneous pathophysiology and narrow therapeutic windows.
Look at rheumatoid arthritis. The American College of Rheumatology says hit it early and hard with disease-modifying antirheumatic drugs to prevent irreversible joint damage. A step therapy protocol that demands six months of methotrexate monotherapy before allowing a biologic forces a patient with high disease activity to endure months of poorly controlled inflammation. Synovitis chews through cartilage and bone while everyone waits. The damage is permanent. The insurer saves on drug costs today and creates a patient who’ll need joint replacements and disability support later. The failure is baked into the protocol.
For chronic migraine, step therapy often demands trials of at least two older oral preventives—beta-blockers, tricyclic antidepressants, antiepileptics—before approving a CGRP monoclonal antibody. These older drugs come with side effects that can flatten a person: fatigue, weight gain, cognitive fog. Someone already fighting to keep a job through 15 migraine days a month is asked to endure months of additional side effects that may further disable them. When they finally fail—because the drugs were never a good match for their migraine biology—they’ve lost months of function. Step therapy treats their suffering as a cost of doing business.
The Prior Authorization Labyrinth
Prior authorization is the administrative machinery that enforces step therapy, formulary restrictions, and limits on pricey imaging or procedures. It’s a system where a clinician has to beg a third-party payer for permission to deliver standard-of-care treatment. The process is deliberately foggy. Criteria are often unpublished or buried in provider manuals. Denials routinely come from reviewers who aren’t specialists in the relevant field. A cardiologist’s request for a cardiac MRI might get reviewed by a general surgeon working for a utilization review firm. The appeal process has multiple tiers, tight deadlines, and a talent for getting lost in a busy practice.
The human cost shows up in the data. A 2021 American Medical Association survey found that 93% of physicians reported care delays linked to prior authorization, and 82% said patients abandoned treatment because of authorization battles. For chronic diseases, abandonment means progression. A Crohn’s patient who can’t get timely authorization for a biologic will flare. A flare that might have been managed with a steroid course escalates to a bowel obstruction needing surgical resection. The prior authorization process, built to cut unnecessary spending, has spawned a new category of necessary spending: the cost of complications from untreated disease.
Cost-Sharing Design That Penalizes Adherence
High-deductible health plans are now standard in employer-sponsored insurance. In 2023, the average single-coverage deductible topped $2,000. For families, it pushed past $4,000. The theory says consumers with “skin in the game” will become savvy shoppers, comparing prices and trimming low-value utilization. That theory has been road-tested and it flunked. Chronically ill patients don’t just cut low-value care. They cut all care, including the high-value maintenance stuff that keeps them alive.
A Health Affairs study tracked medication adherence among chronic disease patients switched to high-deductible plans. Adherence to cardiovascular meds dropped by 5–10 percentage points in the first year. It didn’t bounce back. Patients didn’t learn to shop better. They learned to go without. The cost-sharing design treats a statin prescription like an elective knee scope, as if both were discretionary consumer goods. A statin isn’t a consumer good. It’s a chronic disease management tool with a direct, evidence-based link to fewer heart attacks and strokes. When the copay or deductible throws up a price barrier, the patient skips the meds, and the heart attack that follows costs the system $20,000 to $100,000. The insurance design has externalized the cost of its own cost-sharing.
Coinsurance—where the patient pays a percentage of a drug’s list price instead of a flat copay—is especially brutal for high-cost biologics and specialty meds. A severe asthma patient on a biologic costing $3,500 a month might face 20% coinsurance after deductible, translating to a $700 monthly bill. Few households can absorb that. Manufacturer copay assistance programs exist, but insurers increasingly deploy copay accumulator adjusters that stop that assistance from counting toward the deductible or out-of-pocket max. The patient gets trapped between a drug company offering help and an insurer refusing to acknowledge it. The medication stops mid-year when the assistance runs dry or the financial pressure becomes too much.
Network Narrowing and the Disruption of Therapeutic Relationships
Insurers control costs by building narrow networks of providers who’ve agreed to lower reimbursement rates. For a sprained ankle or strep throat, a skinny network might work fine. For chronic disease management, it’s a recurring disruption. A lupus patient who’s spent years building trust with a rheumatologist who knows their disease trajectory may find that insurer drops that rheumatologist during open enrollment. The patient either switches insurers—if they even have a choice—or starts over with a new clinician who doesn’t know their history.
The disruption isn’t just emotional. Lupus management depends on subtle judgment calls about prior treatment responses, lab trends, organ involvement. A new rheumatologist, however talented, has to reconstruct that history from incomplete records. Meanwhile, early signs of a flare can slip past. The patient might get re-exposed to meds they already failed. The network change injects a clinical risk that wasn’t there before. The insurer carries zero liability for it; the patient and the new clinician absorb it all.
The Accumulation of Administrative Burden
Each barrier—deductible resets, formulary changes, step therapy, prior authorization, coinsurance, network disruption—sits in its own insurer silo. For the patient, they pile up. One person with type 2 diabetes, hypertension, and depression can face all six at once. They’re supposed to time refills to minimize out-of-pocket costs, track formulary shifts across three drug classes, submit to step therapy for a new antidepressant, get prior authorization for an SGLT2 inhibitor, pay coinsurance on a GLP-1 agonist, and verify their endocrinologist is still in-network. This isn’t a healthcare system. It’s a part-time administrative job dumped on someone already managing three chronic diseases.
The cognitive load is itself a health risk. Diabetes self-management demands constant attention to diet, exercise, glucose checks, foot care. Depression undercuts executive function, making the very administrative tasks insurance demands even harder. When the cognitive burden of insurance navigation exceeds capacity, the first thing to go isn’t the paperwork—it’s the self-care. Blood glucose checks stop because the patient is drowning in prior authorization faxes. The insurance design hasn’t just built a financial wall; it’s drained the cognitive resources needed for disease self-management.
Clinicians absorb the overflow. A primary care doc with a panel of 2,000 patients, a quarter of them juggling multiple chronic conditions, spends an estimated 15 hours a week on prior authorizations, formulary appeals, and peer-to-peer reviews. That’s 15 hours not spent seeing patients, not spent reading the latest literature, not spent calling to ask how a new medication is sitting. The insurance industry has offloaded its administrative costs onto the clinical workforce, feeding directly into burnout and the stampede out of primary care. The primary care shortage then becomes another barrier to chronic disease management—a second-order effect of insurance design.
Policy Fixes That Address Design, Not Symptoms
The solutions aren’t hidden. They just demand a willingness to stare down the incentives that make the current system profitable for insurers and PBMs. First step: mandate that chronic disease medications be exempt from deductibles and subject only to fixed, low copays. The evidence is blunt. Reducing cost-sharing for high-value chronic disease drugs improves adherence and cuts total healthcare spending by preventing acute events. This isn’t radical. It’s the logical extension of the preventive services mandate in the Affordable Care Act, which already requires no-cost coverage for certain preventive interventions. We just need to admit that maintenance meds for established chronic conditions are preventive services.
Second, prior authorization for chronic disease meds should be eliminated for patients who are stable on a therapy. If someone has been on a biologic for rheumatoid arthritis for 18 months with documented improvement in disease activity scores, there is zero clinical reason to demand re-authorization every six or twelve months. The re-authorization exists only to create friction that might cause a treatment lapse. A “stable patient exemption” would keep prior authorization for new starts while stripping the repetitive burden from established therapeutic relationships.
Third, formulary changes should be banned mid-year and limited at annual renewal for patients on stable chronic disease regimens. If an insurer wants to renegotiate its PBM contracts, it must grandfather existing patients on their current medications for at least 12 months after the change. That would stop the January formulary shock that destabilizes people exactly when their deductibles reset.
Fourth, copay accumulator programs should be banned. Flat out. If a manufacturer gives a patient financial help, that help should count toward the deductible and out-of-pocket max. Anything else is a double dip: the insurer pockets the manufacturer’s money and still demands the patient pay the full cost-sharing amount. This practice is just a way to shift costs from the insurer to the sickest patients.
These aren’t sprawling regulatory overhauls. They’re targeted fixes to specific design features that generate predictable harm. The insurance industry will scream about premium increases. The counterargument is that they’ll reduce total healthcare spending by keeping chronically ill people out of emergency departments and hospitals. Actuaries can model both scenarios, but the models have to account for the cost of untreated disease—not just the cost of the drug today versus tomorrow.
FAQ
Why do insurers use step therapy if it causes harm?
Because it slashes pharmacy spending in the short term, which polishes their medical loss ratio and profitability. The harms—disease progression, more hospitalizations—often land in later years or on a different payer’s books, like Medicare when a patient turns 65. The insurer that imposes step therapy today might not be the one paying for the joint replacement five years later. The incentive is to minimize current drug costs, not to optimize long-term health.
Doesn’t prior authorization prevent unnecessary care?
It does block some low-value imaging and procedures, sure. But it’s a blunt instrument. For chronic disease meds prescribed by specialists following evidence-based guidelines, the rate of truly inappropriate prescribing is low. The prior authorization burden lands mostly on appropriate, guideline-concordant care. The system can’t tell the difference between an unnecessary knee MRI and a necessary biologic for Crohn’s disease. Until it can make that distinction reliably, it will keep blocking necessary care more than it stops unnecessary care.
What can patients do when they hit a barrier?
They can ask for a formulary exception, backed by a letter of medical necessity from their prescriber. If denied, they can appeal. If the denial holds, they can request an external review by an independent medical reviewer. They can also contact their state insurance commissioner’s office. In practice, these processes are slow and draining. Often the most effective immediate move is to work with a specialty pharmacy or a manufacturer patient assistance program to bridge the gap—though this doesn’t fix the underlying design.
Are there insurance models that manage chronic disease better?
Some integrated delivery systems—Kaiser Permanente, the Veterans Health Administration—do better because they align insurance, pharmacy, and clinical care under one roof. They have no incentive to shift costs between silos. In the commercial market, a few employers are testing value-based insurance design, which lowers cost-sharing for high-value services for specific chronic conditions. These models are promising but still rare. The dominant fee-for-service, multi-payer model remains structurally hostile to chronic disease management.